专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005007647A9 TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：三取代芳基和杂芳基衍生物作为代谢调节剂和预防和治疗与其相关的疾病
公开(公告)号：WO2005007647A9
公开(公告)日：2005-04-07
申请号：PCT/US2004022327
申请日：2004-07-09
申请人： ARENA PHARM INC , JONES ROBERT M , SEMPLE GRAEME , XIONG YIFENG , SHIN YOUNG-JUN , REN ALBERT S , CALDERON IMELDA , CHOI JIN SUN KAROLINE , FIORAVANTI BEATRIZ , LEHMANN JUERG , BRUCE MARC A
发明人： JONES ROBERT M , SEMPLE GRAEME , XIONG YIFENG , SHIN YOUNG-JUN , REN ALBERT S , CALDERON IMELDA , CHOI JIN SUN KAROLINE , FIORAVANTI BEATRIZ , LEHMANN JUERG , BRUCE MARC A
IPC分类号： A61K31/4439 , A61K31/513 , A61P3/10 , C07D239/52 , C07D239/54 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , A61K31/505 , A61K31/506 , A61K31/5377
CPC分类号： C07D239/52 , C07D239/54 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The present invention relates to certain trisubstituted aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
摘要翻译：本发明涉及作为代谢调节剂的式（I）的某些三取代的芳基和杂芳基衍生物。因此，本发明化合物可用于预防或治疗代谢紊乱及其并发症，例如糖尿病和肥胖症。

2. 发明申请

WO2005121121A3 SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO 审中-公开
标题翻译：作为代谢物和丙肝的调节剂和与之相关的疾病的治疗的替代性ARYL和HETEROARYL衍生物
公开(公告)号：WO2005121121A3
公开(公告)日：2006-03-16
申请号：PCT/US2005019318
申请日：2005-06-02
申请人： ARENA PHARM INC , JONES ROBERT M , SEMPLE GRAEME , XIONG YIFENG , SHIN YOUNG-JUN , REN ALBERT S , LEHMANN JUERG , FIORAVANTI BEATRIZ , BRUCE MARC A , CHOI JIN SUN KAROLINE
发明人： JONES ROBERT M , SEMPLE GRAEME , XIONG YIFENG , SHIN YOUNG-JUN , REN ALBERT S , LEHMANN JUERG , FIORAVANTI BEATRIZ , BRUCE MARC A , CHOI JIN SUN KAROLINE
IPC分类号： C07D401/04 , A61K31/506 , A61P3/10 , C07D239/48 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/04
CPC分类号： C07D401/04 , C07D239/48 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/04
摘要： The present invention relates to certain substituted aryl and heteroaryl derivative of Formula (I) that are modulators of metabolism, especially of the activity of a GPCR, referred to herein as RUP3. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.
摘要翻译：本发明涉及作为代谢调节剂（特别是GPCR的活性，称为RUP3）的式（I）的某些取代的芳基和杂芳基衍生物。因此，本发明的化合物可用于治疗代谢相关疾病及其并发症，例如糖尿病和肥胖症。

3. 发明申请

WO2006052566A3 GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS 审中-公开
标题翻译： GPR41及其与胰岛素相关性疾病治疗的调节剂
公开(公告)号：WO2006052566A3
公开(公告)日：2006-10-12
申请号：PCT/US2005039551
申请日：2005-11-01
申请人： ARENA PHARM INC , LEONARD JAMES N , CHU ZHI LIANG , BRUCE MARC A , BOATMAN P DOUGLAS
发明人： LEONARD JAMES N , CHU ZHI LIANG , BRUCE MARC A , BOATMAN P DOUGLAS
IPC分类号： A61K49/00 , G01N33/50
CPC分类号： G01N33/66 , G01N2500/04
摘要： The present invention relates to a method for identifying a glycemic stabilizing compound by: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is modulated, where a modulation in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. In addition, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is increased, wherein an increase in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. Further, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is decreased, wherein a decrease in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound.
摘要翻译：本发明涉及通过以下方式鉴定血糖稳定化合物的方法：a）使候选化合物与GPR41接触，以及b）确定是否调节GPR41功能性，其中GPR41官能度的调节指示候选化合物是血糖稳定剂复合。此外，本发明涉及一种鉴定血糖稳定化合物的方法，包括：a）使候选化合物与GPR41接触，和b）确定GPR41的功能是否增加，其中GPR41功能的增加指示候选化合物为血糖稳定化合物。此外，本发明涉及用于鉴定血糖稳定化合物的方法，其包括：a）使候选化合物与GPR41接触，和b）确定GPR41的功能性是否降低，其中GPR41官能度的降低指示候选化合物为血糖稳定化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式